The US drugs giant Ionis Pharmaceuticals has announced further improvements in the treatment of patients with hereditary ageing (HAE) - a potentially best-in-class treatment for patients living with the condition. Scientists have revealed that the drug's potential to be the best in class prophylactic treatment.
Source: prnewswire.comPublished on 2023-02-21
Related news
- OpenAPI Specification 3 . 1 . 0 Released
- Corelight Secures $75 Million in Series D Funding Led by Energy Impact Partners
- U . S . Air Force Reveals Cutting Edge B - 21 Stealth Bomber
- Corelight Secures $75 Million in Series D Funding Led by Energy Impact Partners with Participation from H . I . G . Growth Partners , CrowdStrike and Capital One Ventures
- Study : Extra 20 Minutes of Daily Physical Activity Helps Prevent Hospitalizations
- Budget 2023 - 24 : Continued focus on infra to enable growth , create jobs & enhance quality of life
- Study : Extra 20 Minutes of Daily Physical Activity Helps Prevent Hospitalizations
- Working in partnership with nature : The complete package for today climate challenges
- A subregional grouping that must get back on course
- In a fast - changing and fragmented market , data targeting on the sell - side works for everyone
- New tools for Azure Data at Build 2021
- SODA Foundation Announces New Data Framework Release , Ecosystem Initiative and Data and Storage Insights at First - Ever SODACON Global
- Litgrid plans - evolution of the organization and the possib ...
- Study : Extra 20 Minutes of Daily Activity Prevents Hospital Trips
- Consumers are open to data sharing when they are free to give consent